177 related articles for article (PubMed ID: 24495439)
1. Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals.
Mukai Y; Shimatani Y; Sako W; Asanuma K; Nodera H; Sakamoto T; Izumi Y; Kohda T; Kozaki S; Kaji R
Toxicon; 2014 Apr; 81():32-6. PubMed ID: 24495439
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Systemic Toxicity between Botulinum Toxin Subtypes A1 and A2 in Mice and Rats.
Torii Y; Goto Y; Nakahira S; Kozaki S; Kaji R; Ginnaga A
Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):524-8. PubMed ID: 25395371
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of a New Botulinum Toxin Type A Free of Complexing Proteins.
Oh HM; Park JH; Song DH; Chung ME
Toxins (Basel); 2015 Dec; 8(1):. PubMed ID: 26712786
[TBL] [Abstract][Full Text] [Related]
4. Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test.
Torii Y; Kiyota N; Sugimoto N; Mori Y; Goto Y; Harakawa T; Nakahira S; Kaji R; Kozaki S; Ginnaga A
Toxicon; 2011 Jan; 57(1):93-9. PubMed ID: 21029745
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Effect of Botulinum Toxin A Injections into the Extensor Digitorum Brevis Muscle after Local Mechanical Leg Vibration: A Case Report.
Hefter H; Beek J; Rosenthal D; Samadzadeh S
Toxins (Basel); 2021 Jun; 13(6):. PubMed ID: 34203875
[TBL] [Abstract][Full Text] [Related]
6. Clinical Safety and Tolerability of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Botulinum Neurotoxin Subtype A2, in Comparison with Subtype A1 Toxins.
Takeuchi T; Okuno T; Miyashiro A; Kohda T; Miyamoto R; Izumi Y; Kozaki S; Kaji R
Toxins (Basel); 2021 Nov; 13(11):. PubMed ID: 34822610
[TBL] [Abstract][Full Text] [Related]
7. Nerve stimulation boosts botulinum toxin action in spasticity.
Frasson E; Priori A; Ruzzante B; Didonè G; Bertolasi L
Mov Disord; 2005 May; 20(5):624-9. PubMed ID: 15726575
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the immunogenicity of botulinum toxin type A and the efficacy of A1 and A2 neurotoxins in animals with A1 toxin antibodies.
Torii Y; Goto Y; Nakahira S; Kozaki S; Ginnaga A
Toxicon; 2014 Jan; 77():114-20. PubMed ID: 24269688
[TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacy and toxicity between botulinum toxin subtypes A1 and A2 in cynomolgus macaques.
Torii Y; Sasaki M; Shin MC; Akaike N; Kaji R
Toxicon; 2018 Oct; 153():114-119. PubMed ID: 30193802
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers.
Jost WH; Kohl A; Brinkmann S; Comes G
J Neural Transm (Vienna); 2005 Jul; 112(7):905-13. PubMed ID: 15526142
[TBL] [Abstract][Full Text] [Related]
11. Acute neurophysiologic effects of botulinum toxin type A intramuscular injection on extensor digitorum brevis muscle in healthy adults.
Boulias C; Ismail F; Phadke CP
Toxicon; 2022 May; 211():6-10. PubMed ID: 35283163
[TBL] [Abstract][Full Text] [Related]
12. Different types of botulinum toxin in humans.
Eleopra R; Tugnoli V; Quatrale R; Rossetto O; Montecucco C
Mov Disord; 2004 Mar; 19 Suppl 8():S53-9. PubMed ID: 15027055
[TBL] [Abstract][Full Text] [Related]
13. Clinical differences between A1 and A2 botulinum toxin subtypes.
Kaji R
Toxicon; 2015 Dec; 107(Pt A):85-8. PubMed ID: 26394198
[TBL] [Abstract][Full Text] [Related]
14. Recombinant botulinum neurotoxin serotype A1 in vivo characterization.
Périer C; Martin V; Cornet S; Favre-Guilmard C; Rocher MN; Bindler J; Wagner S; Andriambeloson E; Rudkin B; Marty R; Vignaud A; Beard M; Lezmi S; Kalinichev M
Pharmacol Res Perspect; 2021 Oct; 9(5):e00857. PubMed ID: 34632725
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of biological activity of four botulinum toxin type A preparations in mice.
Chung ME; Song DH; Park JH
Dermatol Surg; 2013 Jan; 39(1 Pt 2):155-64. PubMed ID: 23301819
[TBL] [Abstract][Full Text] [Related]
16. A Pilot Study of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Subtype A2 for Post-Stroke Lower Limb Spasticity: Comparison with OnabotulinumtoxinA.
Kaji R; Miyashiro A; Sato N; Furumoto T; Takeuchi T; Miyamoto R; Kohda T; Izumi Y; Kozaki S
Toxins (Basel); 2022 Oct; 14(11):. PubMed ID: 36355989
[TBL] [Abstract][Full Text] [Related]
17. Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats.
Torii Y; Akaike N; Harakawa T; Kato K; Sugimoto N; Goto Y; Nakahira S; Kohda T; Kozaki S; Kaji R; Ginnaga A
J Pharmacol Sci; 2011; 117(4):275-85. PubMed ID: 22123262
[TBL] [Abstract][Full Text] [Related]
18. Clinical duration of action of different botulinum toxin types in humans.
Eleopra R; Rinaldo S; Montecucco C; Rossetto O; Devigili G
Toxicon; 2020 May; 179():84-91. PubMed ID: 32184153
[TBL] [Abstract][Full Text] [Related]
19. Extensor digitorum brevis test and resistance to botulinum toxin type A.
Gordon PH; Gooch CL; Greene PE
Muscle Nerve; 2002 Dec; 26(6):828-31. PubMed ID: 12451609
[TBL] [Abstract][Full Text] [Related]
20. Muscle volume alterations in spastic muscles immediately following botulinum toxin type-A treatment in children with cerebral palsy.
Williams SA; Reid S; Elliott C; Shipman P; Valentine J
Dev Med Child Neurol; 2013 Sep; 55(9):813-20. PubMed ID: 23789782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
